



## POLICY UPDATES

FEBRUARY 28, 2019



### Monthly webinar for practitioners and office staff

Webinars are held the second Wednesday of each month: 10 to 11 a.m. and 2 to 3 p.m. Our next webinar is March 13, 2019. Learn about our networks and benefit plans, special utilization management programs, and ways to maximize your administrative efficiencies using our web-based tools and resources — perfect for new staff or as a refresher.

Space is limited so **Register today.**

### Health survey for Medicare and Special Needs Plan members

Please encourage your Medicare and Special Needs Plan members to log in to [emblemhealth.com/members](http://emblemhealth.com/members) and take a Health Risk Assessment (HRA) Survey. This will help our care management team direct them to appropriate care and support services. Members may also take this survey by phone at **888-246-2934**, 24 hours a day/7 days a week.

### New York State Medicaid Update – January 2019

The Office of Health Insurance Programs of the New York State Department of Health has released the January 2019 [Medicaid Update](#) (Volume 35 - Number 1). Please find [the current issue](#) available for download as a PDF file.

### Know your network participation

Please ensure that your staff knows which of our networks you participate in for 2019. Watch this [video](#) if you need help finding information about your participation.

## Follow access and availability standards

Our [Appointment Availability Standards During Office Hours & After Office Hours Access Standards](#) brochure was created to help you schedule timely appointments and know how to be accessible to our members. It is a vital tool for your appointment schedulers.

## CLAIMS CORNER

### BENEFITS

#### Medicaid doula pilot program

EmblemHealth will participate in the New York State Doula Pilot Program to address maternal mortality and reduce racial disparities in health outcomes. [More](#).

## CLINICAL CORNER

### MEDICAL POLICY UPDATES

#### New:

##### [Automatic Blood Pressure Monitor](#)

#### Revised:

[Osteochondral Grafting](#) - Added decellularized osteochondral allograft plugs (e.g., Chondrofix) and reduced allograft discs (e.g., ProChondrix, Cartiform) to Limitations/Exclusions section as investigational.

[Blepharoplasty](#) - Added “to relieve painful symptoms of blepharospasm” as a covered indication.

### MEDICAL TECHNOLOGIES DATABASE

The [Medical Technologies Database](#) has been posted to [emblemhealth.com](#). Dispositions apply to all LOBs unless otherwise indicated. This notification reflects both the December and January postings, which also captures annual procedure coding updates.

#### Approved:

1. Electroretinography (ERG) with interpretation and report, pattern (PERG)
2. Gene expression profiling — AFF2 (AF4/FMR2 family, member 2 [FMR2]) (e.g., fragile X mental retardation 2 [FRAXE])
3. Gene expression profiling — ATXN1 (ataxin 1) (e.g., spinocerebellar ataxia) gene analysis, evaluation to detect abnormal (e.g., expanded) alleles

4. Gene expression profiling — ATXN8OS (ATXN8 opposite strand [non-protein coding]) (e.g., spinocerebellar ataxia) gene
5. Gene expression profiling — BTK (Bruton's tyrosine kinase), PLCG2 (phospholipase C gamma 2) (e.g., chronic lymphocytic leukemia) gene analysis
6. Gene expression profiling — CACNA1A (calcium voltage-gated channel subunit alpha1 A) (e.g., spinocerebellar ataxia) gene
7. Gene expression profiling — CNBP (CCHC-type zinc finger nucleic acid binding protein) (e.g., myotonic dystrophy type 2) gene
8. Gene expression profiling — CSTB (cystatin B) (e.g., Unverricht-Lundborg disease)
9. Gene expression profiling — DMPK (DM1 protein kinase) (e.g., myotonic dystrophy type 1) gene analysis (Commercial and Medicaid only)
10. Gene expression profiling — EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) (e.g., myelodysplastic syndrome, myeloproliferative neoplasms) gene analysis
11. Gene expression profiling — FXN (frataxin) (e.g., Friedreich ataxia) gene analysis (Commercial and Medicaid only)
12. Gene expression profiling — HTT (huntingtin) (e.g., Huntington disease) gene analysis (Commercial and Medicaid only)
13. Gene expression profiling — MYD88 (myeloid differentiation primary response 88) (e.g., Waldenstrom's macroglobulinemia, lymphoplasmacytic leukemia) gene analysis, p.Leu265Pro (L265P) variant
14. Gene expression profiling — NUDT15 (nudix hydrolase 15) (e.g., drug metabolism) gene analysis
15. Gene expression profiling — PABPN1 (poly[A] binding protein nuclear 1) (e.g., oculopharyngeal muscular dystrophy) gene analysis
16. Gene expression profiling — PPP2R2B (protein phosphatase 2 regulatory subunit Bbeta) (e.g., spinocerebellar ataxia) gene analysis
17. Gene expression profiling — SMN1 (survival of motor neuron 1, telomeric) (e.g., spinal muscular atrophy) gene analysis; dosage/deletion analysis (e.g., carrier testing)/ SMN2 (survival of motor neuron 2, centromeric) analysis (Commercial and Medicaid only)
18. Gene expression profiling — TBP (TATA box binding protein) (e.g., spinocerebellar ataxia) gene analysis
19. Gene expression profiling — TERT (telomerase reverse transcriptase) (e.g., thyroid carcinoma, glioblastoma multiforme) gene analysis, targeted sequence analysis
20. Gene expression profiling — TGFBI (transforming growth factor beta-induced) (e.g., corneal dystrophy) gene analysis
21. MYvantage® Hereditary Comprehensive Cancer Panel (Quest)
22. Nerve blocks for primary or secondary headache per LCD (Medicare only)
23. Ross pulmonary autograft (aka Ross procedure)

### Rejected:

1. Cardiac — hemodynamic, transcatheter implantation of wireless pulmonary artery pressure sensor for long-term hemodynamic monitoring, including deployment and calibration of the sensor, right heart catheterization, selective pulmonary catheterization, radiological supervision and interpretation, and pulmonary artery angiography, when performed
2. Cardiac — myocardial imaging by magnetocardiography (MCG) for detection of cardiac ischemia, by signal acquisition using minimum 36 channel grid, generation of magnetic-field time-series images
3. Continuous recording of movement disorder symptoms, including bradykinesia, dyskinesia, and tremor for 6 days up to 10 days; includes set-up, patient training, configuration of monitor, data upload, analysis and initial report configuration,

- download review, interpretation and report
4. Extracorporeal shockwave therapy for inte.g.umentary wound healing, high energy
  5. Gene expression profiling — AR (androgen receptor) (e.g., spinal and bulbar muscular atrophy, Kennedy disease, X chromosome inactivation) gene analysis
  6. Intraprocedural coronary fractional flow reserve (FFR) with 3D functional mapping of color-coded FFR values for the coronary tree, derived from coronary angiogram data, for real-time
  7. Intraoperative visual axis identification using patient fixation
  8. Pharmacogenetic testing — IFNL3 testing for drug response (interferon) gene analysis
  9. PK Papyrus Covered Coronary Stent System (Covered for on-label use only commensurate with FDA Humanitarian Device Exemption)
  10. Tarsi Implant — removal /removal and reinsertion

**EmblemHealth**

55 Water St. New York, NY, 10041



EmblemHealth insurance plans are underwritten by Group Health Incorporated (GHI), Health Insurance Plan of Greater New York (HIP) and HIP Insurance Company of New York.

This email was sent to %%emailaddr%% by EmblemHealth. To ensure delivery to your inbox, please add [EmblemHealth@emblemhealthcommunications.com](mailto:EmblemHealth@emblemhealthcommunications.com) to your address book or safe sender list. If you'd like to unsubscribe from our mailing list, [click here](#). Please note this mailbox is not monitored. Do not respond to this email. If you need assistance, please contact your representative.

Copyright ©2019 EmblemHealth. All Rights Reserved.

[Privacy Policy](#)

JP44626